<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2026.1771100</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Argon plasma-activated liquid inactivates <italic>Helicobacter pylori</italic> and resistant hospital pathogens through acidification and reactive species</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Heisterberg</surname>
<given-names>Leander</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2945747"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Biber</surname>
<given-names>Ulrich</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Neugebauer</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3139450"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liese</surname>
<given-names>Jan</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/491921"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Thompson</surname>
<given-names>Christopher C.</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Enderle</surname>
<given-names>Markus</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3139457"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grashorn</surname>
<given-names>Sebastian</given-names>
</name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Erbe Elektromedizin GmbH</institution>, <city>T&#x00FC;bingen</city>, <country country="de">Germany</country></aff>
<aff id="aff2"><label>2</label><institution>Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women&#x2019;s Hospital</institution>, <city>Boston</city>, <state>MA</state>, <country country="us">United States</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Medicine, Harvard Medical School</institution>, <city>Boston</city>, <state>MA</state>, <country country="us">United States</country></aff>
<aff id="aff4"><label>4</label><institution>T&#x00FC;bingen University Hospital, Institute of Medical Microbiology and Hygiene</institution>, <city>T&#x00FC;bingen</city>, <country country="de">Germany</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Leander Heisterberg, <email xlink:href="mailto:lheisterberg@bwh.harvard.edu">lheisterberg@bwh.harvard.edu</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-16">
<day>16</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>17</volume>
<elocation-id>1771100</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>29</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>02</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Heisterberg, Biber, Neugebauer, Liese, Thompson, Enderle and Grashorn.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Heisterberg, Biber, Neugebauer, Liese, Thompson, Enderle and Grashorn</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-16">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>The rise of antibiotic-resistant bacteria is a major public health concern. Physical plasma can generate reactive oxygen and nitrogen species (RONS) with antimicrobial activity. Plasma-activated liquid (PAL) can be used as a carrier for RONS. This study investigated the antibacterial effects of PAL against clinically relevant Gram-negative (<italic>Escherichia coli</italic>, multidrug-resistant (MDR) <italic>Escherichia coli</italic>, <italic>Pseudomonas aeruginosa</italic>, <italic>Acinetobacter baumannii</italic>, <italic>Enterobacter cloacae</italic>, <italic>Klebsiella pneumoniae</italic>, and <italic>Helicobacter pylori</italic>) and Gram-positive (<italic>Staphylococcus aureus</italic> and <italic>Enterococcus faecium</italic>) bacteria.</p>
</sec>
<sec>
<title>Methods and results</title>
<p>A commercial argon plasma electrosurgical source was used to produce PAL from 0.9% NaCl solution. PAL-NaCl showed strong bactericidal effects: MDR <italic>E. coli</italic> was completely eradicated (&#x003E;6 log<sub>10</sub> reduction) within 60&#x202F;min. <italic>H. pylori</italic> was reduced by ~4.5 log<sub>10</sub> within 15&#x202F;min and completely eradicated (&#x003E;5 log<sub>10</sub>) within 60&#x202F;min of exposure. Gram-negative bacteria were highly susceptible with a mean reduction of ~6.3 log<sub>10</sub>, whereas Gram-positive bacteria showed lower susceptibility with a mean reduction of ~2.6 log<sub>10</sub>. Antibacterial activity was associated with acidic pH and influenced by carrier solution chemistry, consistent with a contribution of short-lived secondary reactive nitrogen species. The scavenger 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride (FeTPPS), targeting peroxynitrite (ONOO<sup>&#x2212;</sup>), partially inhibited the antibacterial effect, supporting its mechanistic importance. Buffered solutions (higher pH) showed minimal antibacterial activity despite higher absolute RONS concentrations which underlines the importance of the acidic environment.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>PAL generated with an argon plasma electrosurgical source exhibits potent antibacterial activity, driven by low pH and RONS dynamics. PAL effectively inactivates MDR pathogens and other clinically relevant pathogens, including <italic>H. pylori</italic>. The stomach&#x2019;s acidic environment may enhance PAL activity by maintaining the low-pH conditions required for pH-dependent reactive nitrogen chemistry associated with antibacterial efficacy.</p>
</sec>
</abstract>
<kwd-group>
<kwd>cold atmospheric plasma</kwd>
<kwd><italic>Helicobacter pylori</italic></kwd>
<kwd>microbial biotechnology</kwd>
<kwd>multidrug-resistant bacteria</kwd>
<kwd>novel antimicrobials</kwd>
<kwd>plasma activated liquid</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="57"/>
<page-count count="10"/>
<word-count count="7873"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Antimicrobials, Resistance and Chemotherapy</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>The rise of antibiotic-resistant pathogens is an increasingly critical global health issue. In clinical settings, pathogens such as <italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) and the so-called ESKAPE pathogens (<italic>Enterococcus faecium</italic>, <italic>Staphylococcus aureus</italic>, <italic>Klebsiella pneumoniae</italic>, <italic>Acinetobacter baumannii</italic>, <italic>Pseudomonas aeruginosa</italic>, and <italic>Enterobacter</italic> species) pose significant challenges due to rising resistance profiles (<xref ref-type="bibr" rid="ref39">Salam et al., 2023</xref>; <xref ref-type="bibr" rid="ref37">Rotondo et al., 2025</xref>). For <italic>H. pylori</italic>, the eradication success rate is steadily decreasing with most studies reporting rates &#x2264;80%, despite aggressive therapies using combinations of proton pump inhibitors (PPIs) and antibiotics (<xref ref-type="bibr" rid="ref27">Malfertheiner et al., 2012</xref>). With the increasing emergence of multidrug-resistant (MDR) bacterial strains, there is a need to explore alternative approaches with mechanisms of action other than antibiotics (<xref ref-type="bibr" rid="ref3">Argueta et al., 2021</xref>).</p>
<p>Low-thermal plasma (LTP) has emerged as a promising candidate that exhibits potent antimicrobial activities (<xref ref-type="bibr" rid="ref8">Das et al., 2022</xref>; <xref ref-type="bibr" rid="ref19">Koga-Ito et al., 2023</xref>). Here, LTP is used in an application-oriented sense and refers to plasma operation in which thermal effects remain below the threshold for visible tissue coagulation. In plasma-physics terms, this corresponds to non-equilibrium (non-thermal) atmospheric plasmas, often termed cold atmospheric plasma (CAP), rather than thermal plasmas in (near) thermal equilibrium (<xref ref-type="bibr" rid="ref1">Adamovich et al., 2022</xref>). Clinically, LTP treatments have been used in wound management, demonstrating successful reduction of microbial burden and improved wound healing outcomes (<xref ref-type="bibr" rid="ref2">Amini et al., 2020</xref>; <xref ref-type="bibr" rid="ref5">Bekeschus et al., 2021</xref>; <xref ref-type="bibr" rid="ref41">Talukdar et al., 2025</xref>). These are driven by UV radiation, charged particles, electrons, ions, mild heat and reactive oxygen and nitrogen species (RONS), including hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), nitrite (NO<sub>2</sub><sup>&#x2212;</sup>), nitrate (NO<sub>3</sub><sup>&#x2212;</sup>), and peroxynitrite (ONOO<sup>&#x2212;</sup>) (<xref ref-type="bibr" rid="ref17">Kaushik et al., 2018</xref>). Plasma-based technologies have demonstrated broad-spectrum efficacy against a variety of pathogens, including both Gram-positive (e.g., <italic>Staphylococcus aureus</italic>) and Gram-negative bacteria (e.g., <italic>Escherichia coli</italic>, <italic>Pseudomonas aeruginosa</italic>), as well as fungi such as <italic>Candida albicans</italic> and <italic>Aspergillus</italic> spp. (<xref ref-type="bibr" rid="ref18">Kim and Kim, 2021</xref>).</p>
<p>Plasma activated liquids (PALs) are created by applying physical plasma to a liquid. PALs are liquids in which plasma-generated reactive species are dissolved and can be delivered to less accessible sites. The antimicrobial effect of PAL has been shown in numerous studies (<xref ref-type="bibr" rid="ref22">Liu et al., 2010</xref>; <xref ref-type="bibr" rid="ref42">Traylor et al., 2011</xref>; <xref ref-type="bibr" rid="ref47">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="ref55">Zhao et al., 2020</xref>). This process is already used commercially to some extent for non-medical applications, e.g., the use of PAL in agriculture for antibacterial and antifungal effects (<xref ref-type="bibr" rid="ref34">Pua&#x010D; and &#x0160;koro, 2025</xref>). Although there has been a lot of preclinical biomedical research, standardized and clinically scalable PAL generation and workflows remain limited (<xref ref-type="bibr" rid="ref20">Laroussi et al., 2022</xref>; <xref ref-type="bibr" rid="ref30">Milhan et al., 2022</xref>).</p>
<p>Various plasma sources have been used to generate PAL, including dielectric barrier discharge (DBD), plasma jets, and transient spark discharge devices (<xref ref-type="bibr" rid="ref50">Weltmann et al., 2010</xref>; <xref ref-type="bibr" rid="ref9">Gohain and Biswas, 2025</xref>). Currently, there are only a few medically approved plasma devices on the market, most notably the kINPen<sup>&#x00AE;</sup> MED (neoplas med GmbH, Greifswald, Germany), which is primarily indicated for wound healing applications but has also been used experimentally to generate PAL (<xref ref-type="bibr" rid="ref35">Reuter et al., 2018</xref>; <xref ref-type="bibr" rid="ref7">Clemen et al., 2023</xref>).</p>
<p>More recently, argon plasma coagulation (APC) devices have also been studied for their LTP effects (<xref ref-type="bibr" rid="ref49">Weiss et al., 2019</xref>; <xref ref-type="bibr" rid="ref28">Martinet et al., 2025</xref>). These are approved medical devices that have been on the market for over 30&#x202F;years (<xref ref-type="bibr" rid="ref11">Grund et al., 1997</xref>; <xref ref-type="bibr" rid="ref10">Grund et al., 1999</xref>). By minimizing the effect setting (e.g., electrical power of 1&#x202F;W or even less), they can be operated in a low-thermal mode, which limits or even omits the thermal effect and coagulation of tissue (<xref ref-type="bibr" rid="ref29">Marzi et al., 2022</xref>; <xref ref-type="bibr" rid="ref48">Weiss et al., 2023</xref>). It has been shown that these low-thermal modes generate RONS in an electrical power level dependent manner, with more RONS species being generated at higher power settings and fewer RONS being generated at lower power settings (<xref ref-type="bibr" rid="ref28">Martinet et al., 2025</xref>). While higher APC power settings increase the generation of RONS, they are not suitable for direct low-thermal plasma application due to increasing thermal effects and tissue coagulation (<xref ref-type="bibr" rid="ref53">Zenker, 2008</xref>; <xref ref-type="bibr" rid="ref28">Martinet et al., 2025</xref>). In contrast, when plasma is applied to liquids, thermal effects are decoupled from RONS generation, as the liquid acts as a heat sink due to the high heat capacity of aqueous solutions and allows the production of PAL with high RONS concentrations (<xref ref-type="bibr" rid="ref6">Bruggeman et al., 2016</xref>; <xref ref-type="bibr" rid="ref49">Weiss et al., 2019</xref>).</p>
<p>Previous PAL studies have shown that antibacterial activity depends strongly on liquid composition, acidification, and reactive species chemistry, including synergistic interactions between hydrogen peroxide and nitrite under acidic conditions (<xref ref-type="bibr" rid="ref32">Oehmigen et al., 2010</xref>; <xref ref-type="bibr" rid="ref46">Wang and Salvi, 2021</xref>; <xref ref-type="bibr" rid="ref20">Laroussi et al., 2022</xref>). However, reported efficacy varies widely, in part because PAL is frequently generated using laboratory plasma sources with heterogeneous operating conditions, limiting comparability and reproducibility across studies.</p>
<p>A translational barrier is the limited availability of clinically certified and scalable PAL generation platforms. Electrosurgical APC systems are widely available in hospitals and provide adjustable energy delivery, but APC-generated PAL has not been systematically evaluated against clinically relevant organisms such as <italic>H. pylori</italic> and MDR hospital isolates.</p>
<p>This study investigates the antibacterial effect and gains first insights into mechanisms of action of a commercially available plasma source&#x2014;APC&#x2014;on clinically relevant bacterial strains commonly found in hospital settings. The primary focus is on <italic>H. pylori</italic>, whose susceptibility to PAL has not been systematically evaluated. <italic>H. pylori</italic> is a prevalent gastric pathogen that causes chronic gastritis and peptic ulcer disease and is a major risk factor for gastric cancer, with eradication rates declining due to increasing antibiotic resistance (<xref ref-type="bibr" rid="ref13">Hooi et al., 2017</xref>; <xref ref-type="bibr" rid="ref21">Liou et al., 2020</xref>). In addition, we investigated MDR <italic>E. coli</italic> strain and ESKAPE pathogens. Physicochemical properties of PAL were analyzed, and antibacterial effects were assessed under defined conditions. First mechanistic insights were obtained using chemical controls and selected radical scavengers for selected RONS.</p>
</sec>
<sec id="sec2">
<label>2</label>
<title>Material &#x0026; methods</title>
<sec id="sec3">
<label>2.1</label>
<title>PAL generation setup</title>
<p>PAL was generated using a medical argon plasma system (VIO<sup>&#x00AE;</sup>3 with APC3 module, Erbe Elektromedizin GmbH, T&#x00FC;bingen, Germany) connected to a flexible Filter integrated Argon Plasma Coagulation (FiAPC) probe. Plasma was applied using the VIO3 mode forcedAPC effect setting 8.0 with an argon flow rate of 0.3&#x202F;L/min. The PAL reactor vessel supplied air bubbles from the bottom at an airflow of 0.5&#x202F;L/min and the probe tip (immersed into the liquid) was held at a fixed 4&#x202F;mm distance from a stainless-steel neutral electrode (<xref ref-type="fig" rid="fig1">Figure 1</xref>). For each run, 50&#x202F;mL of either 0.9% NaCl (NaCl, B. Braun, Melsungen, Germany) or Ringer&#x2019;s lactate (Ri-Lac, B. Braun, Melsungen, Germany) were used as carrier solutions.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>PAL generation setup. <bold>(A)</bold> PAL reactor vessel with (1) lid, (2) sleeve, (3) vessel, (4) liquid, (5) FiAPC probe, (6) gas outlet with bubbling, (7) neutral electrode. <bold>(B)</bold> Close-up of the flexible FiAPC probe. <bold>(C)</bold> The electrosurgical generator (VIO<sup>&#x00AE;</sup>3) equipped with the argon plasma module (APC3).</p>
</caption>
<graphic xlink:href="fmicb-17-1771100-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Composite image of the experimental setup for generating Plasma-Activated Liquid (PAL). Panel A is a schematic diagram of the reactor vessel, illustrating the components numbered 1&#x2013;7, including the submerged Flexible Argon Plasma Coagulation (FiAPC) probe, the saline solution, gas bubbling outlet, and the neutral electrode. Panel B shows a photograph of the coiled, flexible FiAPC probe used for plasma delivery. Panel C shows the VIO&#x00AE;3 electrosurgical generator and APC3 module used to power the plasma discharge.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Physicochemical properties of PAL used in antibacterial assays</title>
<p>PAL was generated using plasma activation times of 150&#x202F;s (low-dose) and 225&#x202F;s (standard). The 225&#x202F;s condition was selected as the standard because it yielded consistent PAL chemistry and strong antibacterial effects in our setup, while 150&#x202F;s was included to assess dose dependence. Unless stated otherwise, antibacterial experiments were performed using PAL generated with an activation time of 225&#x202F;s (PAL-NaCl).</p>
<p>PAL was characterized by measuring pH and the concentrations of H&#x2082;O&#x2082; and NO&#x2082;<sup>&#x2212;</sup> immediately after plasma activation. The pH was measured using a calibrated pH meter (FiveEasy F20, Mettler-Toledo, Gie&#x00DF;en, Germany).</p>
<p>Concentrations of H<sub>2</sub>O<sub>2</sub> and NO<sub>2</sub><sup>&#x2212;</sup> were measured photometrically using a Spectroquant<sup>&#x00AE;</sup> Prove 100 system (Merck/Supelco, Darmstadt, Germany). This method was previously described and validated for PAL measurements (<xref ref-type="bibr" rid="ref43">Veronico et al., 2021</xref>). Samples were appropriately diluted to fit within the assay range, followed by reaction with specific reagents for H<sub>2</sub>O<sub>2</sub> (Supelco Hydrogen Peroxide Cell Test, Merck, Darmstadt, Germany) and NO<sub>2</sub><sup>&#x2212;</sup> (Supelco Nitrite Test, Merck, Darmstadt, Germany). Reactions were allowed to proceed for 10&#x202F;min before photometric analysis. All measurements were performed in independent triplicates.</p>
<p>PAL-NaCl showed a pH of 2.94&#x202F;&#x00B1;&#x202F;0.03, with hydrogen peroxide concentrations of 670&#x202F;&#x00B1;&#x202F;17&#x202F;&#x03BC;mol/L and nitrite concentrations of 148&#x202F;&#x00B1;&#x202F;35&#x202F;&#x03BC;mol/L. In contrast, PAL generated from Ringer&#x2019;s lactate at 225&#x202F;s remained weakly acidic (pH 5.03&#x202F;&#x00B1;&#x202F;0.05) with substantially higher concentrations of hydrogen peroxide (1,287&#x202F;&#x00B1;&#x202F;111&#x202F;&#x03BC;mol/L) and nitrite (1,269&#x202F;&#x00B1;&#x202F;96&#x202F;&#x03BC;mol/L). PAL generated from 0.9% NaCl with an activation time of 150&#x202F;s (low-dose PAL) exhibited a pH of 3.13&#x202F;&#x00B1;&#x202F;0.02 and contained hydrogen peroxide and nitrite at concentrations of 616&#x202F;&#x00B1;&#x202F;41&#x202F;&#x03BC;mol/L and 473&#x202F;&#x00B1;&#x202F;7&#x202F;&#x03BC;mol/L, respectively.</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Bacterial strains, culture preparation and PAL exposure</title>
<p>All microbiological experiments were conducted at the Institute for Medical Microbiology and Hygiene, University Hospital T&#x00FC;bingen, Germany. The following bacterial strains were tested in the sensitivity assay: Gram-positive <italic>Staphylococcus aureus</italic> ATCC 6538 (<italic>S. aureus</italic>), <italic>Enterococcus faecium</italic> ATCC 6057 (<italic>E. faecium</italic>); and Gram-negative <italic>Escherichia coli</italic> NCTC 10538 (<italic>E. coli</italic>), <italic>Pseudomonas aeruginosa</italic> ATCC15442 (<italic>P. aeruginosa</italic>), <italic>Acinetobacter baumannii</italic> ATCC 19606 (<italic>A. baumannii</italic>), <italic>Enterobacter cloacae</italic> DSM BAA-143 (<italic>E. cloacae</italic>), <italic>Klebsiella pneumoniae</italic> ATCC 700603 (<italic>K. pneumoniae</italic>), <italic>Helicobacter pylori</italic> SK225 (<italic>H. pylori</italic>). In addition, a multidrug-resistant clinical isolate [<italic>Escherichia coli</italic> strain <italic>4MRGN E. coli</italic> (MDR), internal freezing number VC8874] was tested.</p>
<p>For each experiment, fresh cultures were prepared from frozen stocks. Bacterial strains were grown on Columbia blood agar with sheep blood (Ref. PB50339A, Thermo Fisher Scientific, Waltham, United States), while <italic>H. pylori</italic> was cultured on selective Pylori agar (Ref. 413193, bioM&#x00E9;rieux, N&#x00FC;rtingen, Germany). Plates were incubated at 37&#x202F;&#x00B0;C for 24&#x202F;h (all strains except <italic>H. pylori</italic>) or 72&#x202F;h (<italic>H. pylori</italic>). For each experiment, bacterial colonies were suspended in 0.9% NaCl solution and adjusted to a McFarland standard of 0.5. The actual bacterial concentration of each inoculum was verified for every experimental batch by colony-forming unit (CFU) enumeration using serial dilution and plating.</p>
<p>For PAL exposure, 9&#x202F;mL of freshly generated PAL (temperature immediately after activation: 55.5&#x202F;&#x00B1;&#x202F;2.5&#x202F;&#x00B0;C) was transferred into sterile reaction tubes and cooled in an ice bath to &#x003C;37&#x202F;&#x00B0;C before mixing with 1&#x202F;mL bacterial suspensions. This resulted in a starting concentration of approximately 1.5&#x202F;&#x00D7;&#x202F;10<sup>7</sup>&#x202F;CFU/mL. Control samples were prepared using 0.9% NaCl at room temperature instead of PAL. The first sampling time point (0&#x202F;min) corresponded to approximately 15&#x2013;30&#x202F;s of contact time, accounting for cooling, mixing, and handling. Samples were collected at 0, 15, 60, and 180&#x202F;min, serially diluted in 0.9% NaCl (up to 10<sup>&#x2212;6</sup>), and 100&#x202F;&#x03BC;L of each dilution was plated in duplicate on the corresponding agar medium. Plates were incubated at 37&#x202F;&#x00B0;C for 24&#x202F;h (or 72&#x202F;h for <italic>H. pylori</italic>), and viable bacteria were quantified by CFU counting.</p>
<p>All experiments were performed <italic>in vitro</italic>. Antibacterial activity of PAL was assessed using a suspension assay against the strain panel listed in Section 2.3 above. Subsequent experiments (controls, time-course, and scavenger assays) were performed on selected representative strains as specified in the respective Results subsections.</p>
<p>Control conditions included untreated 0.9% NaCl, PAL generated from Ringer&#x2019;s lactate solution, acidified 0.9% NaCl (pH 2.8, adjusted with hydrochloric acid), and acidified 0.9% NaCl supplemented with hydrogen peroxide (final concentration 25&#x202F;mg/L). The experimental procedure was identical for all conditions.</p>
<p>Each experiment was performed in at least three independent biological replicates. Within each biological replicate, samples were plated in technical duplicate, and colony counts were averaged prior to statistical analysis.</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>Co-exposure with RONS scavengers</title>
<p>To assess the contribution of selected short-lived reactive oxygen and nitrogen species to the antibacterial activity of PAL, chemical scavengers were used to selectively target specific reactive pathways. The following scavengers were applied based on established literature: 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride (FeTPPS) for peroxynitrite, L-histidine for singlet oxygen, D-mannitol for hydroxyl radicals, and taurine for hypochlorous acid (<xref ref-type="bibr" rid="ref4">Bauer et al., 2019</xref>; <xref ref-type="bibr" rid="ref24">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="ref15">Kang et al., 2022</xref>; <xref ref-type="bibr" rid="ref51">Xu et al., 2022</xref>).</p>
<p>All scavengers were obtained from Sigma-Aldrich (Merck, Darmstadt, Germany). Stock solutions were freshly prepared in distilled water and added to PAL to achieve final concentrations of 40&#x202F;&#x03BC;M FeTPPS, 2&#x202F;mM L-histidine, 20&#x202F;mM D-mannitol, or 50&#x202F;mM taurine. To avoid pH-related confounding effects, the pH of the L-histidine stock solution was adjusted to 2.8&#x202F;&#x00B1;&#x202F;0.2 prior to use.</p>
<p>For each experiment, freshly generated PAL (activation time 225&#x202F;s) was distributed into reaction tubes containing either no additive (PAL control) or one of the scavengers. Immediately after mixing by vortexing, pH as well as H<sub>2</sub>O<sub>2</sub> and NO<sub>2</sub><sup>&#x2212;</sup> levels were verified using QUANTOFIX<sup>&#x00AE;</sup> test strips and reflectometric analysis (MACHEREY-NAGEL, D&#x00FC;ren, Germany). PAL&#x2013;scavenger mixtures were then used directly for antibacterial assays as described above.</p>
</sec>
<sec id="sec7">
<label>2.5</label>
<title>Statistical analysis</title>
<p>All experiments were performed using at least three independent biological replicates (<italic>n</italic>&#x202F;&#x2265;&#x202F;3). Log&#x2081;&#x2080; reduction values were calculated for each strain and condition. Descriptive statistics, including mean and standard deviation, were calculated. The normal distribution of data sets was evaluated using a Shapiro&#x2013;Wilk normality test. Since the data sets were normally distributed, differences between data sets were assessed using Student&#x2019;s <italic>t</italic>-tests. One sample <italic>t</italic>-tests against a hypothetical value of zero were used to assess if a log<sub>10</sub> reduction was significant at all. <italic>p</italic>-values &#x003C;0.05 were considered statistically significant. All analyses were performed using GraphPad PRISM, GraphPad, Boston, United States.</p>
</sec>
</sec>
<sec sec-type="results" id="sec8">
<label>3</label>
<title>Results</title>
<sec id="sec9">
<label>3.1</label>
<title>Antibacterial susceptibility testing</title>
<p>The antibacterial activity of PAL was evaluated against a panel of Gram-negative and Gram-positive bacterial strains (<xref ref-type="fig" rid="fig2">Figure 2</xref>) using a suspension assay with a total exposure time of 3&#x202F;h (1&#x202F;h for <italic>H. pylori</italic> due to rapid inactivation). Bacterial viability after PAL exposure was quantified as log<sub>10</sub> reduction compared to the respective 0.9% NaCl-treated control samples.</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Bacterial suspension assay of different strains, mean log<sub>10</sub> fold reduction across independent experiments after 3&#x202F;h exposure: <bold>(A)</bold> with PAL (<italic>n</italic>&#x202F;=&#x202F;3 independent experiments). Star symbols indicate complete eradication (reduction to below the limit of detection, &#x003C;10&#x202F;CFU/mL). PAL exposure resulted in antibacterial effects ranging from complete eradication (&#x2265;6-log reduction) for both <italic>E. coli</italic> strains, <italic>K. pneumoniae</italic> and <italic>A. baumannii</italic>, to a strong reduction for <italic>E. faecium</italic> (~2-log reduction). <bold>(B)</bold> Stability controls showing the log<sub>10</sub> fold change of bacteria in untreated 0.9% NaCl between 0&#x202F;h and 3&#x202F;h. Values near zero indicate no significant growth or death during incubation. <bold>(C)</bold> Further mechanistic controls for <italic>E. coli</italic> (MDR) (<italic>n</italic>&#x202F;=&#x202F;3). Four agar plates of a dilution series were evaluated per biological replicate (<italic>n</italic>). Error bars show SD. <sup>&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.05, <sup>&#x002A;&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.01, <sup>&#x002A;&#x002A;&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.001, and <sup>&#x002A;&#x002A;&#x002A;&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.0001, ns, not significant (one-sample <italic>t</italic>-test vs. 0).</p>
</caption>
<graphic xlink:href="fmicb-17-1771100-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Panel A presents a bar chart showing the Log10 reduction of eight bacterial strains after PAL exposure. Gram-negative bacteria (including H. pylori and E. coli) exhibit high susceptibility with greater than 5-log reduction (marked with stars indicating complete eradication), whereas Gram-positive bacteria display lower susceptibility with approximately 2 to 3-log reduction. Panel B displays the stability controls, showing that bacterial concentrations in untreated 0.9% NaCl remain stable with negligible log changes between 0 and 3 hours. Panel C compares mechanistic controls for E. coli (MDR), demonstrating that acidified saline (pH 2.8) and acidified saline with hydrogen peroxide achieve strong bacterial reduction, whereas non-acidified Ringer's lactate and low-dose PAL result in minimal reduction.</alt-text>
</graphic>
</fig>
<p>PAL exposure (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) resulted in potent bactericidal effects for all tested Gram-negative strains. Complete eradication or high susceptibility (&#x2265;5 log<sub>10</sub> reduction) was observed for <italic>E. coli</italic>, <italic>E. coli</italic> (MDR), <italic>K. pneumoniae</italic>, <italic>A. baumannii</italic>, <italic>E. cloacae</italic>, <italic>P. aeruginosa</italic>, and <italic>H. pylori</italic>. These reductions were statistically significant for the majority of strains (one-sample <italic>t</italic>-tests: <italic>p</italic>&#x202F;&#x003C;&#x202F;0.0001 to <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05), with the exception of <italic>P. aeruginosa</italic> (<italic>p</italic>&#x202F;=&#x202F;0.19) due to higher variance between replicates. In contrast, Gram-positive strains showed lower susceptibility. <italic>S. aureus</italic> exhibited a reduction of ~3.2 log<sub>10</sub> (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001) and <italic>E. faecium</italic> a reduction of ~2.0 log<sub>10</sub> (<italic>p</italic>&#x202F;=&#x202F;0.076). No significant difference in susceptibility was observed between the non-resistant and the MDR <italic>E. coli</italic> strains (<italic>p</italic>&#x202F;=&#x202F;0.11).</p>
<p>We performed a NaCl-only control series (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) with several bacterial strains with 3&#x202F;h exposure before plating on agar. No marked changes in bacterial concentrations were detected.</p>
<p>We further investigated the influencing factors driving this toxicity using <italic>E. coli</italic> (MDR) controls (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Antibacterial effects were observed in these tests, but with considerable differences: acidified 0.9% NaCl (pH 2.8) achieved a significant ~4.4 log<sub>10</sub> reduction (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001). With 0.9% NaCl adjusted to a pH of 2.8 and the addition of H<sub>2</sub>O<sub>2</sub> corresponding to the PAL concentration, a&#x202F;~&#x202F;3.8 log<sub>10</sub> reduction was obtained (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.001). Conversely, low-dose PAL (150&#x202F;s activation, 1&#x202F;h exposure) and PAL produced from Ringer&#x2019;s lactate solution (pH 5.3) resulted in non-significant reductions of &#x003C;1 log<sub>10</sub> (<italic>p</italic>&#x202F;=&#x202F;0.16 and <italic>p</italic>&#x202F;=&#x202F;0.31, respectively).</p>
</sec>
<sec id="sec10">
<label>3.2</label>
<title>Time course of antibacterial effect</title>
<p>The antibacterial time-dependency of PAL were evaluated for <italic>S. aureus</italic>, <italic>E. coli</italic> (MDR) and <italic>H. pylori</italic> with exposure times of 0, 15, 60 and 180&#x202F;min (<xref ref-type="fig" rid="fig3">Figure 3</xref>). For <italic>S. aureus</italic> (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), PAL exposure resulted in a progressive, time-dependent decrease in bacterial viability. Immediately after exposure (0&#x202F;min, &#x003C;30&#x202F;s contact time), a reduction of ~2.6 log<sub>10</sub> was observed, though this initial effect was not yet statistically significant (<italic>p</italic>&#x202F;=&#x202F;0.074). The efficacy increased to a&#x202F;~&#x202F;4.0 log<sub>10</sub> reduction after 15&#x202F;min (<italic>p</italic>&#x202F;=&#x202F;0.065) and reached a significant ~5.2 log<sub>10</sub> reduction after 60&#x202F;min (<italic>p</italic>&#x202F;=&#x202F;0.012). In the case of <italic>E. coli</italic> (MDR) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), PAL exposure led to an immediate but variable drop in bacterial density. At 0&#x202F;min, a mean reduction of ~3.4 log<sub>10</sub> was recorded; however, due to high variability between replicates, this early reduction did not reach statistical significance (<italic>p</italic>&#x202F;=&#x202F;0.22). A similar effect was observed at 15&#x202F;min (<italic>p</italic>&#x202F;=&#x202F;0.15). At 60 and 180&#x202F;min a complete eradication (&#x003E;6 log<sub>10</sub> reduction) was achieved (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.0001). <italic>H. pylori</italic> (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) exhibited the most rapid susceptibility. After 15&#x202F;min of exposure, a significant ~4.5 log<sub>10</sub> reduction to 24&#x202F;&#x00B1;&#x202F;10&#x202F;CFU/mL was observed (<italic>p</italic>&#x202F;=&#x202F;0.015). Complete eradication (&#x003E;5 log<sub>10</sub> reduction) was achieved after 60&#x202F;min, with no viable colonies detected in any treated samples (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.01).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Bacterial suspension assay of different strains with various exposure times, mean log<sub>10</sub> fold reduction across independent experiments: <bold>(A)</bold> <italic>S. aureus</italic> (<italic>n</italic>&#x202F;=&#x202F;4 replicates), <bold>(B)</bold> <italic>E. coli</italic> (MDR) (<italic>n</italic>&#x202F;=&#x202F;3&#x2013;4 replicates), and <bold>(C)</bold> <italic>H. pylori</italic> (<italic>n</italic>&#x202F;=&#x202F;3): with PAL exposure and with 0.9% NaCl control treatment at the end of a single experiment (60 or 180&#x202F;min). Error bars show SD. <sup>&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.05, <sup>&#x002A;&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.01, <sup>&#x002A;&#x002A;&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.001, and <sup>&#x002A;&#x002A;&#x002A;&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.0001, ns, not significant (one-sample <italic>t</italic>-test vs. 0).</p>
</caption>
<graphic xlink:href="fmicb-17-1771100-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Three bar graphs labeled A, B, and C display log fold change in CFU per milliliter over time for S. aureus, E. coli (MDR), and H. pylori. Significant decreases marked by red stars indicate eradication below detection at 60 and 180 minutes for E. coli, and at 60 minutes for H. pylori. NaCl control bars remain near zero, and statistical significance is denoted by asterisks. A legend clarifies the red star symbol.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec11">
<label>3.3</label>
<title>PAL modified by radical scavengers</title>
<p>To identify the specific reactive species driving bactericidal activity, we modified the PAL-NaCl by adding selective radical scavengers (<xref ref-type="fig" rid="fig4">Figure 4</xref>). This series was conducted using <italic>E. coli</italic> (MDR). As a reference, PAL-NaCl alone (15&#x202F;min exposure) reduced bacterial viability to 1740&#x202F;&#x00B1;&#x202F;241&#x202F;CFU/mL, corresponding to a significant ~4.9 log<sub>10</sub> reduction (<italic>p</italic>&#x202F;&#x003C;&#x202F;0.01). The addition of taurine (scavenger for HOCl), D-mannitol (hydroxyl radicals), or L-histidine (singlet oxygen) adjusted to pH 2.8 did not inhibit antimicrobial efficacy. In all three cases, the reduction was comparable to or greater than the PAL-NaCl reference (5 log<sub>10</sub> reduction; <italic>p</italic>&#x202F;=&#x202F;0.80, <italic>p</italic>&#x202F;=&#x202F;0.45 and <italic>p</italic>&#x202F;=&#x202F;0.23, respectively). In contrast, the addition of FeTPPS, a catalyst for the decomposition of peroxynitrite (ONOO<sup>&#x2212;</sup>), significantly attenuated the bactericidal effect (<italic>p</italic>&#x202F;=&#x202F;0.028 vs. PAL-NaCl). In the presence of FeTPPS, the bacterial density remained high at 881&#x202F;&#x00D7;&#x202F;10<sup>3</sup>&#x202F;&#x00B1;&#x202F;71.9&#x202F;&#x00D7;&#x202F;10<sup>3</sup>&#x202F;CFU/mL (~1.8 log<sub>10</sub> reduction, <italic>p</italic>&#x202F;=&#x202F;0.23), whereas no reduction was observed in the NaCl control.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Bacterial suspension assay of <italic>E. coli</italic> (MDR), mean log<sub>10</sub> fold reduction across independent experiments after 15&#x202F;min exposure with standard PAL (blue) and with various PALs modified by radical scavengers (colored bars) and with 0.9% NaCl (black). The PAL-NaCl exposure served as reference (log<sub>10</sub> fold reduction: 4.85), marked as blue dashed line. FeTPPS, that catalytically isomerizes peroxynitrite to nitrate, reducing efficacy to &#x003C;1.8 log<sub>10</sub>, whereas the other scavengers did not. Error bars show SD. Pairwise <italic>t</italic>-tests between PAL-NaCl and the modified PAL groups are graphed: <sup>&#x002A;</sup><italic>p</italic>&#x202F;&#x003C;&#x202F;0.05, ns, not significant.</p>
</caption>
<graphic xlink:href="fmicb-17-1771100-g004.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Bar chart showing log ten fold change in CFU per milliliter of E. coli after fifteen minutes with PAL and various scavengers. FeTPPS significantly inhibits the antibacterial effect (resulting in lower reduction), unlike taurine, D-mannitol, or L-histidine. NaCl has negligible effect.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec12">
<label>4</label>
<title>Discussion</title>
<p>PALs have been widely investigated as non-antibiotic antimicrobial approaches, but reported effects vary substantially across studies due to differences in plasma sources, activation conditions, and liquid composition (<xref ref-type="bibr" rid="ref18">Kim and Kim, 2021</xref>; <xref ref-type="bibr" rid="ref19">Koga-Ito et al., 2023</xref>; <xref ref-type="bibr" rid="ref44">von Woedtke et al., 2025</xref>). A practical limitation is that many PAL studies rely on laboratory plasma devices that are not standardized or clinically available, complicating comparison and reproducibility (<xref ref-type="bibr" rid="ref31">Montalbetti et al., 2025</xref>). In this study, we evaluated the antibacterial activity of PAL generated by a clinically certified electrosurgical APC device. We demonstrated rapid and potent antibacterial effects of APC-derived PAL against multiple Gram-negative pathogens, including <italic>H. pylori</italic> and <italic>E. coli</italic> (MDR). Gram-positive bacteria exhibited significant but comparatively lower susceptibility. Our results emphasize the critical role of low pH in achieving effective antibacterial activity. RONS dynamics, particularly the rapid consumption of nitrite under acidic conditions leading to the formation of peroxynitrous acid (ONOOH) and its conjugate base peroxynitrite (ONOO<sup>&#x2212;</sup>) as well as peroxynitric acid (O<sub>2</sub>NOOH), appear central to this bactericidal action. Importantly, buffered solutions maintaining higher pH levels were ineffective.</p>
<sec id="sec13">
<label>4.1</label>
<title>RONS dynamics and pH dependency impact antibacterial efficacy</title>
<p>Our results confirm that plasma activation of liquids generates H<sub>2</sub>O<sub>2</sub> and NO<sub>2</sub><sup>&#x2212;</sup>, and that their antibacterial efficacy strongly depends on carrier solution chemistry and resulting pH. PAL generated from 0.9% NaCl reached acidic pH values below 3, whereas Ringer&#x2019;s lactate remained weakly acidic (&#x2248;pH 5) due to its buffering capacity. Antibacterial activity tracked with acidity rather than with the absolute concentrations of long-lived species: despite higher H<sub>2</sub>O<sub>2</sub>/NO<sub>2</sub><sup>&#x2212;</sup> levels, Ringer&#x2019;s lactate-derived PAL showed minimal killing, while acidified conditions were bactericidal. Similar pH-dependent effects of PAL have been reported previously (<xref ref-type="bibr" rid="ref14">Ikawa et al., 2010</xref>; <xref ref-type="bibr" rid="ref32">Oehmigen et al., 2010</xref>).</p>
<p>Under acidic conditions, interactions between H<sub>2</sub>O<sub>2</sub> and NO<sub>2</sub><sup>&#x2212;</sup> can give rise to secondary reactive nitrogen species such as peroxynitrous acid and peroxynitrite, which have been implicated in antimicrobial activity (<xref ref-type="bibr" rid="ref46">Wang and Salvi, 2021</xref>; <xref ref-type="bibr" rid="ref56">Zhao et al., 2021</xref>; <xref ref-type="bibr" rid="ref37">Rotondo et al., 2025</xref>). Consistent with this, peroxynitrite scavenging partially attenuated antibacterial activity, supporting a contribution of short-lived secondary chemistry rather than long-lived RONS alone. Practically, this strong pH dependence implies that buffering capacity and handling time are critical determinants of reproducibility, as modest pH shifts can suppress PAL activity.</p>
<p>Differences in reported antibacterial efficacy of PAL across the literature may, in part, be explained by methodological variations. In studies demonstrating bacterial inactivation at higher bulk pH, microorganisms were frequently exposed directly to plasma within the liquid, potentially generating localized acidic microenvironments and introducing additional antimicrobial factors such as ultraviolet radiation and electric fields (<xref ref-type="bibr" rid="ref36">Rothwell et al., 2022</xref>). In contrast, the present study focused exclusively on indirect exposure to PAL, allowing isolation of the chemical effects of plasma-generated species.</p>
<p>Consistent with prior work, we observed a tendency toward very strong susceptibility among Gram-negative species (mean reduction ~6.3 log<sub>10</sub> vs. ~2.6 log<sub>10</sub> for Gram-positives). This tendency is commonly attributed to structural differences in the bacterial cell envelope, particularly the thicker peptidoglycan layer of Gram-positive bacteria, which can confer increased resistance to oxidative and nitrosative stress (<xref ref-type="bibr" rid="ref25">Mai-Prochnow et al., 2014</xref>). However, this distinction was not absolute: <italic>P. aeruginosa</italic> (Gram-negative) exhibited intermediate to strong resilience (~5.3 log<sub>10</sub> reduction), comparable to the Gram-positive <italic>S. aureus</italic> (~3.2 log<sub>10</sub> reduction). This highlights that PAL susceptibility is determined by an interplay of cell wall structure and species-specific defense mechanisms, such as robust antioxidant systems or biofilm-like aggregation, rather than Gram status alone (<xref ref-type="bibr" rid="ref54">Zhang et al., 2023</xref>).</p>
</sec>
<sec id="sec14">
<label>4.2</label>
<title>FeTPPS partially inhibits antibacterial activity, highlighting the role of peroxynitrite</title>
<p>The scavenger experiments provide indirect mechanistic insight into the reactive species contributing to PAL-mediated antibacterial activity (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The significant attenuation observed with FeTPPS is consistent with a pivotal role for peroxynitrite (ONOO<sup>&#x2212;</sup>) and its protonated form, peroxynitrous acid (ONOOH). Under the strongly acidic conditions generated by our APC source (pH &#x003C;3), NO<sub>2</sub><sup>&#x2212;</sup> is chemically unstable and reacts with H<sub>2</sub>O<sub>2</sub> to form ONOOH. This short-lived species is a potent oxidant known to induce severe nitrosative stress at bacterial membranes (<xref ref-type="bibr" rid="ref23">Lukes et al., 2014</xref>; <xref ref-type="bibr" rid="ref57">Zhou et al., 2018</xref>). The fact that FeTPPS, which catalyzes the isomerization of peroxynitrite to nitrate, rescued bacterial viability confirms that this specific secondary species is a key effector of toxicity in our system which has also been reported elsewhere (<xref ref-type="bibr" rid="ref24">Ma et al., 2020</xref>).</p>
<p>In contrast, scavengers targeting singlet oxygen (<sup>1</sup>O<sub>2</sub>, L-histidine), hypochlorous acid (HOCl, taurine), and hydroxyl radicals (&#x2022;OH, D-mannitol) did not demonstrate any measurable inhibitory effect when the pH was maintained at 2.8. In the presence of these scavengers, the antibacterial efficacy of PAL was even slightly increased rather than diminished. While such observations may partly be attributed to the inherent variability of biological systems, it is also conceivable that scavenger addition altered the biochemical pathways within PAL, potentially increasing the concentration or availability of other antibacterial species such as peroxynitrite.</p>
<p>Because L-histidine increased pH when used without adjustment, we applied a pH-matched L-histidine condition (pH 2.8&#x202F;&#x00B1;&#x202F;0.2). Under pH-matched conditions no inhibition was observed, indicating that the apparent loss of activity in the unadjusted condition was primarily pH-driven rather than attributable to <sup>1</sup>O<sub>2</sub> scavenging. In contrast, some literature attributed antibacterial activity to superoxide (O&#x2082;<sup>&#x2212;</sup>) or other species (<xref ref-type="bibr" rid="ref24">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="ref36">Rothwell et al., 2022</xref>). Furthermore, other studies utilizing similar scavengers reported more pronounced inhibitory effects than those observed in our experimental system, e.g., for D-mannitol or L-histidine (<xref ref-type="bibr" rid="ref24">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="ref15">Kang et al., 2022</xref>; <xref ref-type="bibr" rid="ref52">Xu et al., 2023</xref>).</p>
<p>These discrepancies across studies may be due to varying concentrations, plasma-generation parameters, and types of PAL, each potentially favoring distinct biochemical pathways. Future investigations into these complex chemical interactions will be necessary to further clarify the roles of specific short-lived species under diverse PAL generation conditions.</p>
</sec>
<sec id="sec15">
<label>4.3</label>
<title>Clinical translation and limitations</title>
<p>This study demonstrates that relatively large and clinically relevant volumes of PAL (50&#x202F;mL) can be generated within a short time frame (&#x003C;5&#x202F;min) using a certified electrosurgical APC plasma source. The ability to adjust power settings and increase power output makes this system more scalable and time-efficient than typical cold plasma generators operating at near body temperature. Furthermore, as the treated liquid functions as a heat sink, excessive temperature buildup can be effectively minimized, ensuring safe handling and stability of the resulting PAL.</p>
<p>Our findings confirm that PAL produced with the APC system exhibits strong antibacterial efficacy against several clinically important pathogens, including <italic>H. pylori</italic> and <italic>E. coli</italic> (MDR). While previous studies have shown PAL efficacy against ESKAPE pathogens (<xref ref-type="bibr" rid="ref40">Scholtz et al., 2021</xref>), this present study extends these observations to the inactivation of <italic>H. pylori in vitro</italic>. Previous studies investigated the direct plasma treatment of <italic>H. pylori</italic> colonized surfaces and attributed a part of the effect on the UV radiation which can be excluded in this scenario (<xref ref-type="bibr" rid="ref38">Sakudo et al., 2018</xref>).</p>
<p>Both non-resistant and antibiotic-resistant <italic>E. coli</italic> strains showed comparable susceptibility to PAL, consistent with a mode of action that differs fundamentally from conventional antibiotics. Previous studies have suggested that PAL exposure may alter bacterial stress responses or antibiotic susceptibility profiles (<xref ref-type="bibr" rid="ref12">Guo et al., 2018</xref>; <xref ref-type="bibr" rid="ref45">Vukovi&#x0107; et al., 2025</xref>); however, such effects were not directly assessed here and require dedicated investigation.</p>
<p>Given the strong pH dependence observed in this study, acidic environments may represent relevant contexts for further investigation of PAL activity. In this regard, the gastric lumen, characterized by low pH, provides a physiologically acidic setting in which PAL-mediated antibacterial effects could be explored experimentally. <italic>H. pylori</italic>, a pathogen adapted to survive within the gastric mucosa and increasingly resistant to standard antibiotic regimens, represents a relevant model organism for such investigations. Chronic <italic>H. pylori</italic> infection is a major risk factor for peptic ulcer disease and gastric cancer (<xref ref-type="bibr" rid="ref16">Katelaris et al., 2023</xref>; <xref ref-type="bibr" rid="ref33">Park et al., 2025</xref>).</p>
<p>An important translational question is whether the long exposure times used in some suspension assays are feasible and required in the gastrointestinal tract. Our time-course analysis revealed that <italic>H. pylori</italic> is exceptionally sensitive, showing a &#x003E;4.5 log<sub>10</sub> reduction within 15&#x202F;min. This demonstrates that prolonged exposure (e.g., hours) is not strictly necessary for this pathogen. Accordingly, an endoscopic approach involving targeted irrigation or a transient &#x201C;flooding&#x201D; of 10&#x2013;15&#x202F;min could be clinically feasible to significantly reduce bacterial load. In refractory scenarios, PAL could be explored as a bacterial load-reducing adjunct prior to standard eradication regimens, but any impact on clinical eradication outcomes remains speculative without <italic>in vivo</italic> evidence.</p>
<p>Beyond the gastrointestinal tract, PAL has been discussed as a potential approach for antibacterial control in other acidic or locally confined environments, including biofilm-associated infections (<xref ref-type="bibr" rid="ref26">Mai-Prochnow et al., 2021</xref>) and applications in endoscopic or dental settings (<xref ref-type="bibr" rid="ref19">Koga-Ito et al., 2023</xref>). However, these possibilities require dedicated <italic>in vivo</italic> studies to assess feasibility, safety, and efficacy.</p>
<p>Several limitations should be acknowledged. All experiments were conducted under controlled <italic>in vitro</italic> conditions using a limited panel of bacterial strains and defined exposure times. The behavior of PAL in complex biological environments, including buffering effects, organic load, tissue interactions, and host responses, was not assessed. Moreover, the activity of APC-generated PAL against other microorganisms such as fungi or viruses, as well as its physicochemical stability and safety in living tissues, remains to be determined.</p>
<p>In summary, this study provides an <italic>in vitro</italic> characterization of antibacterial activity and underlying chemical dependencies of APC-generated PAL. While the results support further investigation of this approach, additional preclinical and clinical studies are required to assess safety, efficacy, and practical applicability under physiologically relevant conditions.</p>
</sec>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec16">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="sec17">
<title>Ethics statement</title>
<p>This study did not involve human participants or animal experiments and therefore did not require ethical approval. All experiments were performed using <italic>in vitro</italic> bacterial cultures in compliance with institutional biosafety and microbiological safety regulations.</p>
</sec>
<sec sec-type="author-contributions" id="sec18">
<title>Author contributions</title>
<p>LH: Formal analysis, Writing &#x2013; original draft, Data curation, Writing &#x2013; review &#x0026; editing, Validation, Conceptualization, Supervision, Methodology, Investigation. UB: Formal analysis, Visualization, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing, Investigation, Methodology. AN: Conceptualization, Investigation, Writing &#x2013; original draft, Supervision, Writing &#x2013; review &#x0026; editing, Project administration, Formal analysis, Methodology. JL: Supervision, Project administration, Investigation, Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft, Resources. CT: Validation, Project administration, Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft. ME: Funding acquisition, Supervision, Project administration, Resources, Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft. SG: Validation, Writing &#x2013; review &#x0026; editing, Methodology, Supervision, Data curation, Project administration, Resources, Writing &#x2013; original draft, Investigation.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Matthias Parenzan, Larissa Pflug, Tatjana Wei&#x00DF;, and Christina Celik for the valuable assistance during the experimental part of this study, and the authors thank Georg Bauer for his guidance with the scavenger experiments.</p>
</ack>
<sec sec-type="COI-statement" id="sec19">
<title>Conflict of interest</title>
<p>LH, UB, AN, and ME are employees of Erbe Elektromedizin. CT has served as a consultant for Apollo Endosurgery, Boston Scientific, EndoQuest Robotics, EnteraSense Ltd., EnVision Endoscopy, Inc., Fractyl Health, Inc., USGI Medical, Medtronic/Covidien, Olympus/Spiration, GI Dynamics, and Xenter Inc; has served as an advisory board member for USGI Medical and Fractyl Health, Inc.; has received research grants and support from USGI Medical, Apollo Endosurgery, Boston Scientific, EndoQuest Robotics, Erbe USA Inc., Fujifilm, Lumendi, Olympus/Spiration, Aspire Bariatrics, Inc., and GI Dynamics; has served as a general partner for Blueframe Healthcare; has served as a founder for EnteraSense Ltd., EnVision Endoscopy, Inc., and GI Windows Surgical; and holds stock and royalties for GI Windows Surgical.</p>
<p>The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec20">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec21">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamovich</surname><given-names>I.</given-names></name> <name><surname>Agarwal</surname><given-names>S.</given-names></name> <name><surname>Ahedo</surname><given-names>E.</given-names></name> <name><surname>Alves</surname><given-names>L. L.</given-names></name> <name><surname>Baalrud</surname><given-names>S.</given-names></name> <name><surname>Babaeva</surname><given-names>N.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>The 2022 plasma roadmap: low temperature plasma science and technology</article-title>. <source>J. Phys. D: Appl. Phys.</source> <volume>55</volume>:<fpage>373001</fpage>. doi: <pub-id pub-id-type="doi">10.1088/1361-6463/Ac5e1c</pub-id></mixed-citation></ref>
<ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amini</surname><given-names>M. R.</given-names></name> <name><surname>Sheikh Hosseini</surname><given-names>M.</given-names></name> <name><surname>Fatollah</surname><given-names>S.</given-names></name> <name><surname>Mirpour</surname><given-names>S.</given-names></name> <name><surname>Ghoranneviss</surname><given-names>M.</given-names></name> <name><surname>Larijani</surname><given-names>B.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Beneficial effects of cold atmospheric plasma on inflammatory phase of diabetic foot ulcers; a randomized clinical trial</article-title>. <source>J. Diabetes Metab. Disord.</source> <volume>19</volume>, <fpage>895</fpage>&#x2013;<lpage>905</lpage>. doi: <pub-id pub-id-type="doi">10.1007/S40200-020-00577-2</pub-id>, <pub-id pub-id-type="pmid">33520811</pub-id></mixed-citation></ref>
<ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argueta</surname><given-names>E. A.</given-names></name> <name><surname>Alsamman</surname><given-names>M. A.</given-names></name> <name><surname>Moss</surname><given-names>S. F.</given-names></name> <name><surname>D&#x2019;Agata</surname><given-names>E. M. C.</given-names></name></person-group> (<year>2021</year>). <article-title>Impact of antimicrobial resistance rates on eradication of <italic>Helicobacter pylori</italic> in a US population</article-title>. <source>Gastroenterology</source> <volume>160</volume>, <fpage>2181</fpage>&#x2013;<lpage>2183.e1</lpage>. doi: <pub-id pub-id-type="doi">10.1053/J.Gastro.2021.02.014</pub-id>, <pub-id pub-id-type="pmid">33577874</pub-id></mixed-citation></ref>
<ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>G.</given-names></name> <name><surname>Sersenov&#x00E1;</surname><given-names>D.</given-names></name> <name><surname>Graves</surname><given-names>D. B.</given-names></name> <name><surname>Machala</surname><given-names>Z.</given-names></name></person-group> (<year>2019</year>). <article-title>Cold atmospheric plasma and plasma-activated medium trigger RONS-based tumor cell apoptosis</article-title>. <source>Sci. Rep.</source> <volume>9</volume>:<fpage>14210</fpage>. doi: <pub-id pub-id-type="doi">10.1038/S41598-019-50291-0</pub-id>, <pub-id pub-id-type="pmid">31578342</pub-id></mixed-citation></ref>
<ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekeschus</surname><given-names>S.</given-names></name> <name><surname>von Woedtke</surname><given-names>T.</given-names></name> <name><surname>Emmert</surname><given-names>S.</given-names></name> <name><surname>Schmidt</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Medical gas plasma-stimulated wound healing: evidence and mechanisms</article-title>. <source>Redox Biol.</source> <volume>46</volume>:<fpage>102116</fpage>. doi: <pub-id pub-id-type="doi">10.1016/J.Redox.2021.102116</pub-id>, <pub-id pub-id-type="pmid">34474394</pub-id></mixed-citation></ref>
<ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruggeman</surname><given-names>P. J.</given-names></name> <name><surname>Kushner</surname><given-names>M. J.</given-names></name> <name><surname>Locke</surname><given-names>B. R.</given-names></name> <name><surname>Gardeniers</surname><given-names>J. G. E.</given-names></name> <name><surname>Graham</surname><given-names>W. G.</given-names></name> <name><surname>Graves</surname><given-names>D. B.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Plasma&#x2013;liquid interactions: a review and roadmap</article-title>. <source>Plasma Sources Sci. Technol.</source> <volume>25</volume>:<fpage>53002</fpage>. doi: <pub-id pub-id-type="doi">10.1088/0963-0252/25/5/053002</pub-id></mixed-citation></ref>
<ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemen</surname><given-names>R.</given-names></name> <name><surname>Singer</surname><given-names>D.</given-names></name> <name><surname>Skowski</surname><given-names>H.</given-names></name> <name><surname>Bekeschus</surname><given-names>S.</given-names></name></person-group> (<year>2023</year>). <article-title>Argon humidification exacerbates antimicrobial and anti-MRSA kINPen plasma activity</article-title>. <source>Life</source> <volume>13</volume>:<fpage>257</fpage>. doi: <pub-id pub-id-type="doi">10.3390/Life13020257</pub-id>, <pub-id pub-id-type="pmid">36836614</pub-id></mixed-citation></ref>
<ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S.</given-names></name> <name><surname>Gajula</surname><given-names>V. P.</given-names></name> <name><surname>Mohapatra</surname><given-names>S.</given-names></name> <name><surname>Singh</surname><given-names>G.</given-names></name> <name><surname>Kar</surname><given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Role of cold atmospheric plasma in microbial inactivation and the factors affecting its efficacy</article-title>. <source>Health Sci. Rev.</source> <volume>4</volume>:<fpage>100037</fpage>. doi: <pub-id pub-id-type="doi">10.1016/J.Hsr.2022.100037</pub-id></mixed-citation></ref>
<ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gohain</surname><given-names>R. B.</given-names></name> <name><surname>Biswas</surname><given-names>S.</given-names></name></person-group> (<year>2025</year>). <article-title>Impact of applied voltage, air gap, and ground arrangement on discharge power and dielectric capacitance in a volume DBD plasma</article-title>. <source>Phys. Scr.</source> <volume>100</volume>:<fpage>25604</fpage>. doi: <pub-id pub-id-type="doi">10.1088/1402-4896/Ada3f3</pub-id></mixed-citation></ref>
<ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grund</surname><given-names>K. E.</given-names></name> <name><surname>Straub</surname><given-names>T.</given-names></name> <name><surname>Farin</surname><given-names>G.</given-names></name></person-group> (<year>1999</year>). <article-title>New haemostatic techniques: argon plasma coagulation</article-title>. <source>Baillieres Best Pract. Res. Clin. Gastroenterol.</source> <volume>13</volume>, <fpage>67</fpage>&#x2013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1053/Bega.1999.0009</pub-id>, <pub-id pub-id-type="pmid">11030635</pub-id></mixed-citation></ref>
<ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grund</surname><given-names>K. E.</given-names></name> <name><surname>Zindel</surname><given-names>C.</given-names></name> <name><surname>Farin</surname><given-names>G.</given-names></name></person-group> (<year>1997</year>). <article-title>Argonplasmakoagulation In Der Flexiblen Endoskopie. Bewertung Eines Neuen Therapeutischen Verfahrens Nach 1606 Anwendungen</article-title>. <source>Dtsch. Med. Wochenschr.</source> <volume>122</volume>, <fpage>432</fpage>&#x2013;<lpage>438</lpage>. doi: <pub-id pub-id-type="doi">10.1055/S-2008-1047634</pub-id>, <pub-id pub-id-type="pmid">9138921</pub-id></mixed-citation></ref>
<ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L.</given-names></name> <name><surname>Xu</surname><given-names>R.</given-names></name> <name><surname>Zhao</surname><given-names>Y.</given-names></name> <name><surname>Liu</surname><given-names>D.</given-names></name> <name><surname>Liu</surname><given-names>Z.</given-names></name> <name><surname>Wang</surname><given-names>X.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Gas plasma pre-treatment increases antibiotic sensitivity and persister eradication in methicillin-resistant <italic>Staphylococcus aureus</italic></article-title>. <source>Front. Microbiol.</source> <volume>9</volume>:<fpage>537</fpage>. doi: <pub-id pub-id-type="doi">10.3389/Fmicb.2018.00537</pub-id>, <pub-id pub-id-type="pmid">29628915</pub-id></mixed-citation></ref>
<ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooi</surname><given-names>J. K. Y.</given-names></name> <name><surname>Lai</surname><given-names>W. Y.</given-names></name> <name><surname>Ng</surname><given-names>W. K.</given-names></name> <name><surname>Suen</surname><given-names>M. M. Y.</given-names></name> <name><surname>Underwood</surname><given-names>F. E.</given-names></name> <name><surname>Tanyingoh</surname><given-names>D.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Global prevalence of <italic>Helicobacter pylori</italic> infection: systematic review and meta-analysis</article-title>. <source>Gastroenterology</source> <volume>153</volume>, <fpage>420</fpage>&#x2013;<lpage>429</lpage>. doi: <pub-id pub-id-type="doi">10.1053/J.Gastro.2017.04.022</pub-id>, <pub-id pub-id-type="pmid">28456631</pub-id></mixed-citation></ref>
<ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikawa</surname><given-names>S.</given-names></name> <name><surname>Kitano</surname><given-names>K.</given-names></name> <name><surname>Hamaguchi</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Effects of pH on bacterial inactivation in aqueous solutions due to low-temperature atmospheric pressure plasma application</article-title>. <source>Plasma Process. Polym.</source> <volume>7</volume>, <fpage>33</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1002/Ppap.200900090</pub-id></mixed-citation></ref>
<ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>T.</given-names></name> <name><surname>Yim</surname><given-names>D.</given-names></name> <name><surname>Baek</surname><given-names>K. H.</given-names></name> <name><surname>Lee</surname><given-names>Y. E.</given-names></name> <name><surname>Kim</surname><given-names>H.-J.</given-names></name> <name><surname>Jo</surname><given-names>C.</given-names></name></person-group> (<year>2022</year>). <article-title>The inactivation efficacy of plasma-activated acetic acid against <italic>Salmonella</italic> Typhimurium cells and biofilm</article-title>. <source>J. Appl. Microbiol.</source> <volume>133</volume>, <fpage>3007</fpage>&#x2013;<lpage>3019</lpage>. doi: <pub-id pub-id-type="doi">10.1111/Jam.15757</pub-id>, <pub-id pub-id-type="pmid">35916587</pub-id></mixed-citation></ref>
<ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katelaris</surname><given-names>P.</given-names></name> <name><surname>Hunt</surname><given-names>R.</given-names></name> <name><surname>Bazzoli</surname><given-names>F.</given-names></name> <name><surname>Cohen</surname><given-names>H.</given-names></name> <name><surname>Fock</surname><given-names>K. M.</given-names></name> <name><surname>Gemilyan</surname><given-names>M.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title><italic>Helicobacter pylori</italic> world gastroenterology organization global guideline</article-title>. <source>J. Clin. Gastroenterol.</source> <volume>57</volume>, <fpage>111</fpage>&#x2013;<lpage>126</lpage>. doi: <pub-id pub-id-type="doi">10.1097/Mcg.0000000000001719</pub-id>, <pub-id pub-id-type="pmid">36598803</pub-id></mixed-citation></ref>
<ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaushik</surname><given-names>N. K.</given-names></name> <name><surname>Ghimire</surname><given-names>B.</given-names></name> <name><surname>Li</surname><given-names>Y.</given-names></name> <name><surname>Adhikari</surname><given-names>M.</given-names></name> <name><surname>Veerana</surname><given-names>M.</given-names></name> <name><surname>Kaushik</surname><given-names>N.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Biological and medical applications of plasma-activated media, water and solutions</article-title>. <source>Biol. Chem.</source> <volume>400</volume>, <fpage>39</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1515/Hsz-2018-0226</pub-id>, <pub-id pub-id-type="pmid">30044757</pub-id></mixed-citation></ref>
<ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name> <name><surname>Kim</surname><given-names>C.-H.</given-names></name></person-group> (<year>2021</year>). <article-title>Applications of plasma-activated liquid in the medical field</article-title>. <source>Biomedicine</source> <volume>9</volume>:<fpage>1700</fpage>. doi: <pub-id pub-id-type="doi">10.3390/Biomedicines9111700</pub-id>, <pub-id pub-id-type="pmid">34829929</pub-id></mixed-citation></ref>
<ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koga-Ito</surname><given-names>C. Y.</given-names></name> <name><surname>Kostov</surname><given-names>K. G.</given-names></name> <name><surname>Miranda</surname><given-names>F. S.</given-names></name> <name><surname>Milhan</surname><given-names>N. V.</given-names></name> <name><surname>Azevedo Neto</surname><given-names>N. F.</given-names></name> <name><surname>Nascimento</surname><given-names>F.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Cold atmospheric plasma as a therapeutic tool in medicine and dentistry</article-title>. <source>Plasma Chem. Plasma Process.</source> <volume>44</volume>, <fpage>1393</fpage>&#x2013;<lpage>1429</lpage>. doi: <pub-id pub-id-type="doi">10.1007/S11090-023-10380-5</pub-id></mixed-citation></ref>
<ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laroussi</surname><given-names>M.</given-names></name> <name><surname>Bekeschus</surname><given-names>S.</given-names></name> <name><surname>Keidar</surname><given-names>M.</given-names></name> <name><surname>Bogaerts</surname><given-names>A.</given-names></name> <name><surname>Fridman</surname><given-names>A.</given-names></name> <name><surname>Lu</surname><given-names>X.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Low-temperature plasma for biology, hygiene, and medicine: perspective and roadmap</article-title>. <source>IEEE Trans. Radiat. Plasma Med. Sci.</source> <volume>6</volume>, <fpage>127</fpage>&#x2013;<lpage>157</lpage>. doi: <pub-id pub-id-type="doi">10.1109/Trpms.2021.3135118</pub-id></mixed-citation></ref>
<ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liou</surname><given-names>J.-M.</given-names></name> <name><surname>Malfertheiner</surname><given-names>P.</given-names></name> <name><surname>Lee</surname><given-names>Y.-C.</given-names></name> <name><surname>Sheu</surname><given-names>B.-S.</given-names></name> <name><surname>Sugano</surname><given-names>K.</given-names></name> <name><surname>Cheng</surname><given-names>H.-C.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Screening and eradication of <italic>Helicobacter pylori</italic> for gastric cancer prevention: the Taipei global consensus</article-title>. <source>Gut</source> <volume>69</volume>, <fpage>2093</fpage>&#x2013;<lpage>2112</lpage>. doi: <pub-id pub-id-type="doi">10.1136/Gutjnl-2020-322368</pub-id>, <pub-id pub-id-type="pmid">33004546</pub-id></mixed-citation></ref>
<ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F.</given-names></name> <name><surname>Sun</surname><given-names>P.</given-names></name> <name><surname>Bai</surname><given-names>N.</given-names></name> <name><surname>Tian</surname><given-names>Y.</given-names></name> <name><surname>Zhou</surname><given-names>H.</given-names></name> <name><surname>Wei</surname><given-names>S.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Inactivation of bacteria in an aqueous environment by a direct-current, cold-atmospheric-pressure air plasma microjet</article-title>. <source>Plasma Process. Polym.</source> <volume>7</volume>, <fpage>231</fpage>&#x2013;<lpage>236</lpage>. doi: <pub-id pub-id-type="doi">10.1002/Ppap.200900070</pub-id></mixed-citation></ref>
<ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukes</surname><given-names>P.</given-names></name> <name><surname>Dolezalova</surname><given-names>E.</given-names></name> <name><surname>Sisrova</surname><given-names>I.</given-names></name> <name><surname>Clupek</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Aqueous-phase chemistry and bactericidal effects from an air discharge plasma in contact with water: evidence for the formation of peroxynitrite through a pseudo-second-order post-discharge reaction of H<sub>2</sub>O<sub>2</sub> and HNO<sub>2</sub></article-title>. <source>Plasma Sources Sci. Technol.</source> <volume>23</volume>:<fpage>15019</fpage>. doi: <pub-id pub-id-type="doi">10.1088/0963-0252/23/1/015019</pub-id></mixed-citation></ref>
<ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>M.</given-names></name> <name><surname>Zhang</surname><given-names>Y.</given-names></name> <name><surname>Lv</surname><given-names>Y.</given-names></name> <name><surname>Sun</surname><given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>The key reactive species in the bactericidal process of plasma activated water</article-title>. <source>J. Phys. D: Appl. Phys.</source> <volume>53</volume>:<fpage>185207</fpage>. doi: <pub-id pub-id-type="doi">10.1088/1361-6463/Ab703a</pub-id></mixed-citation></ref>
<ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mai-Prochnow</surname><given-names>A.</given-names></name> <name><surname>Murphy</surname><given-names>A. B.</given-names></name> <name><surname>Mclean</surname><given-names>K. M.</given-names></name> <name><surname>Kong</surname><given-names>M. G.</given-names></name> <name><surname>Ostrikov</surname><given-names>K. K.</given-names></name></person-group> (<year>2014</year>). <article-title>Atmospheric pressure plasmas: infection control and bacterial responses</article-title>. <source>Int. J. Antimicrob. Agents</source> <volume>43</volume>, <fpage>508</fpage>&#x2013;<lpage>517</lpage>. doi: <pub-id pub-id-type="doi">10.1016/J.Ijantimicag.2014.01.025</pub-id></mixed-citation></ref>
<ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mai-Prochnow</surname><given-names>A.</given-names></name> <name><surname>Zhou</surname><given-names>R.</given-names></name> <name><surname>Zhang</surname><given-names>T.</given-names></name> <name><surname>Ostrikov</surname><given-names>K. K.</given-names></name> <name><surname>Mugunthan</surname><given-names>S.</given-names></name> <name><surname>Rice</surname><given-names>S. A.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Interactions of plasma-activated water with biofilms: inactivation, dispersal effects and mechanisms of action</article-title>. <source>npj Biofilms Microbiomes</source> <volume>7</volume>:<fpage>11</fpage>. doi: <pub-id pub-id-type="doi">10.1038/S41522-020-00180-6</pub-id>, <pub-id pub-id-type="pmid">33504802</pub-id></mixed-citation></ref>
<ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P.</given-names></name> <name><surname>Megraud</surname><given-names>F.</given-names></name> <name><surname>O'morain</surname><given-names>C. A.</given-names></name> <name><surname>Atherton</surname><given-names>J.</given-names></name> <name><surname>Axon</surname><given-names>A. T. R.</given-names></name> <name><surname>Bazzoli</surname><given-names>F.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Management of <italic>Helicobacter pylori</italic> infection&#x2014;the Maastricht IV/ Florence consensus report</article-title>. <source>Gut</source> <volume>61</volume>, <fpage>646</fpage>&#x2013;<lpage>664</lpage>. doi: <pub-id pub-id-type="doi">10.1136/Gutjnl-2012-302084</pub-id>, <pub-id pub-id-type="pmid">22491499</pub-id></mixed-citation></ref>
<ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinet</surname><given-names>A.</given-names></name> <name><surname>Miebach</surname><given-names>L.</given-names></name> <name><surname>Heisterberg</surname><given-names>L.</given-names></name> <name><surname>Neugebauer</surname><given-names>A.</given-names></name> <name><surname>Enderle</surname><given-names>M. D.</given-names></name> <name><surname>Bekeschus</surname><given-names>S.</given-names></name></person-group> (<year>2025</year>). <article-title>Reactive species production and colon cancer cytotoxicity of an electrosurgical cold argon plasma device</article-title>. <source>Plasma Process. Polym.</source> <volume>22</volume>:<fpage>e2400240</fpage>. doi: <pub-id pub-id-type="doi">10.1002/Ppap.202400240</pub-id></mixed-citation></ref>
<ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzi</surname><given-names>J.</given-names></name> <name><surname>Stope</surname><given-names>M. B.</given-names></name> <name><surname>Henes</surname><given-names>M.</given-names></name> <name><surname>Koch</surname><given-names>A.</given-names></name> <name><surname>Wenzel</surname><given-names>T.</given-names></name> <name><surname>Holl</surname><given-names>M.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Noninvasive physical plasma as innovative and tissue-preserving therapy for women positive for cervical intraepithelial neoplasia</article-title>. <source>Cancers</source> <volume>14</volume>:<fpage>1933</fpage>. doi: <pub-id pub-id-type="doi">10.3390/Cancers14081933</pub-id>, <pub-id pub-id-type="pmid">35454839</pub-id></mixed-citation></ref>
<ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milhan</surname><given-names>N. V. M.</given-names></name> <name><surname>Chiappim</surname><given-names>W.</given-names></name> <name><surname>Da Sampaio</surname><given-names>A. G.</given-names></name> <name><surname>Da Vegian</surname><given-names>M. R. C.</given-names></name> <name><surname>Pessoa</surname><given-names>R. S.</given-names></name> <name><surname>Koga-Ito</surname><given-names>C. Y.</given-names></name></person-group> (<year>2022</year>). <article-title>Applications of plasma-activated water in dentistry: a review</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>:<fpage>4131</fpage>. doi: <pub-id pub-id-type="doi">10.3390/Ijms23084131</pub-id></mixed-citation></ref>
<ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montalbetti</surname><given-names>R.</given-names></name> <name><surname>Machala</surname><given-names>Z.</given-names></name> <name><surname>Gherardi</surname><given-names>M.</given-names></name> <name><surname>Laurita</surname><given-names>R.</given-names></name></person-group> (<year>2025</year>). <article-title>Production and chemical composition of plasma activated water: a systematic review and meta-analysis</article-title>. <source>Plasma Process. Polym.</source> <volume>22</volume>:<fpage>2400249</fpage>. doi: <pub-id pub-id-type="doi">10.1002/Ppap.202400249</pub-id></mixed-citation></ref>
<ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oehmigen</surname><given-names>K.</given-names></name> <name><surname>H&#x00E4;hnel</surname><given-names>M.</given-names></name> <name><surname>Brandenburg</surname><given-names>R.</given-names></name> <name><surname>Wilke</surname><given-names>C.</given-names></name> <name><surname>Weltmann</surname><given-names>K.-D.</given-names></name> <name><surname>von Woedtke</surname><given-names>T.</given-names></name></person-group> (<year>2010</year>). <article-title>The role of acidification for antimicrobial activity of atmospheric pressure plasma in liquids</article-title>. <source>Plasma Process. Polym.</source> <volume>7</volume>, <fpage>250</fpage>&#x2013;<lpage>257</lpage>. doi: <pub-id pub-id-type="doi">10.1002/Ppap.200900077</pub-id></mixed-citation></ref>
<ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J. Y.</given-names></name> <name><surname>Georges</surname><given-names>D.</given-names></name> <name><surname>Alberts</surname><given-names>C. J.</given-names></name> <name><surname>Bray</surname><given-names>F.</given-names></name> <name><surname>Clifford</surname><given-names>G.</given-names></name> <name><surname>Baussano</surname><given-names>I.</given-names></name></person-group> (<year>2025</year>). <article-title>Global lifetime estimates of expected and preventable gastric cancers across 185 countries</article-title>. <source>Nat. Med.</source> <volume>31</volume>, <fpage>3020</fpage>&#x2013;<lpage>3027</lpage>. doi: <pub-id pub-id-type="doi">10.1038/S41591-025-03793-6</pub-id>, <pub-id pub-id-type="pmid">40624406</pub-id></mixed-citation></ref>
<ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pua&#x010D;</surname><given-names>N.</given-names></name> <name><surname>&#x0160;koro</surname><given-names>N.</given-names></name></person-group> (<year>2025</year>). <article-title>Plasma&#x2013;liquid interaction for agriculture&#x2014;a focused review</article-title>. <source>Plasma Process. Polym.</source> <volume>22</volume>:<fpage>2400208</fpage>. doi: <pub-id pub-id-type="doi">10.1002/Ppap.202400208</pub-id></mixed-citation></ref>
<ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>S.</given-names></name> <name><surname>von Woedtke</surname><given-names>T.</given-names></name> <name><surname>Weltmann</surname><given-names>K.-D.</given-names></name></person-group> (<year>2018</year>). <article-title>The kINPen&#x2014;a review on physics and chemistry of the atmospheric pressure plasma jet and its applications</article-title>. <source>J. Phys. D: Appl. Phys.</source> <volume>51</volume>:<fpage>233001</fpage>. doi: <pub-id pub-id-type="doi">10.1088/1361-6463/Aab3ad</pub-id></mixed-citation></ref>
<ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothwell</surname><given-names>J. G.</given-names></name> <name><surname>Alam</surname><given-names>D.</given-names></name> <name><surname>Carter</surname><given-names>D. A.</given-names></name> <name><surname>Soltani</surname><given-names>B.</given-names></name> <name><surname>Mcconchie</surname><given-names>R.</given-names></name> <name><surname>Zhou</surname><given-names>R.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>The antimicrobial efficacy of plasma-activated water against <italic>Listeria</italic> and <italic>E. coli</italic> is modulated by reactor design and water composition</article-title>. <source>J. Appl. Microbiol.</source> <volume>132</volume>, <fpage>2490</fpage>&#x2013;<lpage>2500</lpage>. doi: <pub-id pub-id-type="doi">10.1111/Jam.15429</pub-id>, <pub-id pub-id-type="pmid">34957649</pub-id></mixed-citation></ref>
<ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotondo</surname><given-names>P. R.</given-names></name> <name><surname>Aceto</surname><given-names>D.</given-names></name> <name><surname>Ambrico</surname><given-names>M.</given-names></name> <name><surname>Stellacci</surname><given-names>A. M.</given-names></name> <name><surname>Faretra</surname><given-names>F.</given-names></name> <name><surname>De Miccolis Angelini</surname><given-names>R. M.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title>Physicochemical properties of plasma-activated water and associated antimicrobial activity against Fungi and Bacteria</article-title>. <source>Sci. Rep.</source> <volume>15</volume>:<fpage>5536</fpage>. doi: <pub-id pub-id-type="doi">10.1038/S41598-025-88369-7</pub-id>, <pub-id pub-id-type="pmid">39953074</pub-id></mixed-citation></ref>
<ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakudo</surname><given-names>A.</given-names></name> <name><surname>Miyagi</surname><given-names>H.</given-names></name> <name><surname>Horikawa</surname><given-names>T.</given-names></name> <name><surname>Yamashiro</surname><given-names>R.</given-names></name> <name><surname>Misawa</surname><given-names>T.</given-names></name></person-group> (<year>2018</year>). <article-title>Treatment of <italic>Helicobacter pylori</italic> with dielectric barrier discharge plasma causes UV induced damage to genomic DNA leading to cell death</article-title>. <source>Chemosphere</source> <volume>200</volume>, <fpage>366</fpage>&#x2013;<lpage>372</lpage>. doi: <pub-id pub-id-type="doi">10.1016/J.Chemosphere.2018.02.115</pub-id></mixed-citation></ref>
<ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salam</surname><given-names>M. A.</given-names></name> <name><surname>Al-Amin</surname><given-names>M. Y.</given-names></name> <name><surname>Salam</surname><given-names>M. T.</given-names></name> <name><surname>Pawar</surname><given-names>J. S.</given-names></name> <name><surname>Akhter</surname><given-names>N.</given-names></name> <name><surname>Rabaan</surname><given-names>A. A.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Antimicrobial resistance: a growing serious threat for global public health</article-title>. <source>Healthcare</source> <volume>11</volume>:<fpage>1946</fpage>. doi: <pub-id pub-id-type="doi">10.3390/Healthcare11131946</pub-id>, <pub-id pub-id-type="pmid">37444780</pub-id></mixed-citation></ref>
<ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholtz</surname><given-names>V.</given-names></name> <name><surname>Va&#x0148;kov&#x00E1;</surname><given-names>E.</given-names></name> <name><surname>Ka&#x0161;parov&#x00E1;</surname><given-names>P.</given-names></name> <name><surname>Premanath</surname><given-names>R.</given-names></name> <name><surname>Karunasagar</surname><given-names>I.</given-names></name> <name><surname>Jul&#x00E1;k</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Non-thermal plasma treatment of ESKAPE pathogens: a review</article-title>. <source>Front. Microbiol.</source> <volume>12</volume>:<fpage>737635</fpage>. doi: <pub-id pub-id-type="doi">10.3389/Fmicb.2021.737635</pub-id>, <pub-id pub-id-type="pmid">34712211</pub-id></mixed-citation></ref>
<ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talukdar</surname><given-names>P.</given-names></name> <name><surname>Gohain</surname><given-names>R. B.</given-names></name> <name><surname>Bharadwaj</surname><given-names>P.</given-names></name> <name><surname>Thakur</surname><given-names>D.</given-names></name> <name><surname>Biswas</surname><given-names>S.</given-names></name></person-group> (<year>2025</year>). <article-title>Inactivation of <italic>Candida albicans</italic>, staphylococcus aureus and multidrug-resistant <italic>Escherichia coli</italic> with dielectric barrier discharged cold atmospheric plasma: a comparative study with antimicrobial drugs</article-title>. <source>J. Med. Microbiol.</source> <volume>74</volume>:<fpage>1965</fpage>. doi: <pub-id pub-id-type="doi">10.1099/Jmm.0.001965</pub-id></mixed-citation></ref>
<ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traylor</surname><given-names>M. J.</given-names></name> <name><surname>Pavlovich</surname><given-names>M. J.</given-names></name> <name><surname>Karim</surname><given-names>S.</given-names></name> <name><surname>Hait</surname><given-names>P.</given-names></name> <name><surname>Sakiyama</surname><given-names>Y.</given-names></name> <name><surname>Clark</surname><given-names>D. S.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Long-term antibacterial efficacy of air plasma-activated water</article-title>. <source>Plasma Sources Sci. Technol.</source> <volume>44</volume>:<fpage>472001</fpage>. doi: <pub-id pub-id-type="doi">10.1088/0022-3727/44/47/472001</pub-id></mixed-citation></ref>
<ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veronico</surname><given-names>V.</given-names></name> <name><surname>Favia</surname><given-names>P.</given-names></name> <name><surname>Fracassi</surname><given-names>F.</given-names></name> <name><surname>Gristina</surname><given-names>R.</given-names></name> <name><surname>Sardella</surname><given-names>E.</given-names></name></person-group> (<year>2021</year>). <article-title>Validation of colorimetric assays for hydrogen peroxide, nitrate and nitrite ions in complex plasma-treated water solutions</article-title>. <source>Plasma Process. Polym.</source> <volume>18</volume>:<fpage>2100062</fpage>. doi: <pub-id pub-id-type="doi">10.1002/Ppap.202100062</pub-id></mixed-citation></ref>
<ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Woedtke</surname><given-names>T.</given-names></name> <name><surname>Bekeschus</surname><given-names>S.</given-names></name> <name><surname>Weltmann</surname><given-names>K.-D.</given-names></name> <name><surname>Wende</surname><given-names>K.</given-names></name></person-group> (<year>2025</year>). <article-title>Plasma-treated liquids for medicine: a narrative review on state and perspectives</article-title>. <source>Plasma Process. Polym.</source> <volume>22</volume>:<fpage>2400255</fpage>. doi: <pub-id pub-id-type="doi">10.1002/Ppap.202400255</pub-id></mixed-citation></ref>
<ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vukovi&#x0107;</surname><given-names>D.</given-names></name> <name><surname>Mileti&#x0107;</surname><given-names>M.</given-names></name> <name><surname>Tolji&#x0107;</surname><given-names>B.</given-names></name> <name><surname>Milojevi&#x0107;</surname><given-names>N.</given-names></name> <name><surname>Jovanovi&#x0107;</surname><given-names>O.</given-names></name> <name><surname>Kuzmanovi&#x0107; Pfi&#x0107;er</surname><given-names>J.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title>Plasma-activated water against Carbapenem-resistant <italic>Klebsiella pneumoniae</italic> and vancomycin-resistant <italic>Enterococcus faecalis</italic></article-title>. <source>Pathogens</source> <volume>14</volume>:<fpage>410</fpage>. doi: <pub-id pub-id-type="doi">10.3390/Pathogens14050410</pub-id>, <pub-id pub-id-type="pmid">40430731</pub-id></mixed-citation></ref>
<ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name> <name><surname>Salvi</surname><given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>Evaluation of plasma-activated water (paw) as a novel disinfectant: effectiveness on <italic>Escherichia coli</italic> and <italic>Listeria innocua</italic>, physicochemical properties, and storage stability</article-title>. <source>LWT</source> <volume>149</volume>:<fpage>111847</fpage>. doi: <pub-id pub-id-type="doi">10.1016/J.Lwt.2021.111847</pub-id></mixed-citation></ref>
<ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name> <name><surname>Xia</surname><given-names>C.</given-names></name> <name><surname>Guo</surname><given-names>Y.</given-names></name> <name><surname>Yang</surname><given-names>C.</given-names></name> <name><surname>Cheng</surname><given-names>C.</given-names></name> <name><surname>Zhao</surname><given-names>J.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Bactericidal efficacy of cold atmospheric plasma treatment against multidrug-resistant <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Future Microbiol.</source> <volume>15</volume>, <fpage>115</fpage>&#x2013;<lpage>125</lpage>. doi: <pub-id pub-id-type="doi">10.2217/Fmb-2019-0265</pub-id>, <pub-id pub-id-type="pmid">31989838</pub-id></mixed-citation></ref>
<ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>M.</given-names></name> <name><surname>Arnholdt</surname><given-names>M.</given-names></name> <name><surname>Hi&#x00DF;nauer</surname><given-names>A.</given-names></name> <name><surname>Fischer</surname><given-names>I.</given-names></name> <name><surname>Sch&#x00F6;nfisch</surname><given-names>B.</given-names></name> <name><surname>Andress</surname><given-names>J.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Tissue-preserving treatment with non-invasive physical plasma of cervical intraepithelial neoplasia-a prospective controlled clinical trial</article-title>. <source>Front. Med.</source> <volume>10</volume>:<fpage>1242732</fpage>. doi: <pub-id pub-id-type="doi">10.3389/Fmed.2023.1242732</pub-id>, <pub-id pub-id-type="pmid">37654659</pub-id></mixed-citation></ref>
<ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>M.</given-names></name> <name><surname>Utz</surname><given-names>R.</given-names></name> <name><surname>Ackermann</surname><given-names>M.</given-names></name> <name><surname>Taran</surname><given-names>F.-A.</given-names></name> <name><surname>Kr&#x00E4;mer</surname><given-names>B.</given-names></name> <name><surname>Hahn</surname><given-names>M.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Characterization of a non-thermally operated electrosurgical argon plasma source by electron spin resonance spectroscopy</article-title>. <source>Plasma Process. Polym.</source> <volume>16</volume>:<fpage>1800150</fpage>. doi: <pub-id pub-id-type="doi">10.1002/Ppap.201800150</pub-id></mixed-citation></ref>
<ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weltmann</surname><given-names>K. D.</given-names></name> <name><surname>Kindel</surname><given-names>E.</given-names></name> <name><surname>von Woedtke</surname><given-names>T.</given-names></name> <name><surname>H&#x00E4;hnel</surname><given-names>M.</given-names></name> <name><surname>Stieber</surname><given-names>M.</given-names></name> <name><surname>Brandenburg</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>Atmospheric-pressure plasma sources: prospective tools for plasma medicine</article-title>. <source>Pure Appl. Chem.</source> <volume>82</volume>, <fpage>1223</fpage>&#x2013;<lpage>1237</lpage>. doi: <pub-id pub-id-type="doi">10.1351/Pac-Con-09-10-35</pub-id></mixed-citation></ref>
<ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name> <name><surname>Fang</surname><given-names>C.</given-names></name> <name><surname>Shao</surname><given-names>C.</given-names></name> <name><surname>Li</surname><given-names>L.</given-names></name> <name><surname>Huang</surname><given-names>Q.</given-names></name></person-group> (<year>2022</year>). <article-title>Study of the synergistic effect of singlet oxygen with other plasma-generated ROS in fungi inactivation during water disinfection</article-title>. <source>Sci. Total Environ.</source> <volume>838</volume>:<fpage>156576</fpage>. doi: <pub-id pub-id-type="doi">10.1016/J.Scitotenv.2022.156576</pub-id>, <pub-id pub-id-type="pmid">35688233</pub-id></mixed-citation></ref>
<ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name> <name><surname>Liu</surname><given-names>C.</given-names></name> <name><surname>Huang</surname><given-names>Q.</given-names></name></person-group> (<year>2023</year>). <article-title>Enhance the inactivation of fungi by the sequential use of cold atmospheric plasma and plasma-activated water: synergistic effect and mechanism study</article-title>. <source>Chem. Eng. J.</source> <volume>452</volume>:<fpage>139596</fpage>. doi: <pub-id pub-id-type="doi">10.1016/J.Cej.2022.139596</pub-id></mixed-citation></ref>
<ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zenker</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Argon plasma coagulation</article-title>. <source>GMS Krankenhaushyg. Interdiszip.</source> <volume>3</volume>:<fpage>Doc15</fpage>. Available online at: <ext-link xlink:href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2831517/" ext-link-type="uri">https://pmc.ncbi.nlm.nih.gov/articles/PMC2831517/</ext-link></mixed-citation></ref>
<ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name> <name><surname>Zhang</surname><given-names>C.</given-names></name> <name><surname>Han</surname><given-names>Q.</given-names></name></person-group> (<year>2023</year>). <article-title>Mechanisms of bacterial inhibition and tolerance around cold atmospheric plasma</article-title>. <source>Appl. Microbiol. Biotechnol.</source> <volume>107</volume>, <fpage>5301</fpage>&#x2013;<lpage>5316</lpage>. doi: <pub-id pub-id-type="doi">10.1007/S00253-023-12618-W</pub-id>, <pub-id pub-id-type="pmid">37421472</pub-id></mixed-citation></ref>
<ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.-M.</given-names></name> <name><surname>Ojha</surname><given-names>S.</given-names></name> <name><surname>Burgess</surname><given-names>C. M.</given-names></name> <name><surname>Sun</surname><given-names>D.-W.</given-names></name> <name><surname>Tiwari</surname><given-names>B. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Inactivation efficacy and mechanisms of plasma activated water on bacteria in planktonic state</article-title>. <source>J. Appl. Microbiol.</source> <volume>129</volume>, <fpage>1248</fpage>&#x2013;<lpage>1260</lpage>. doi: <pub-id pub-id-type="doi">10.1111/Jam.14677</pub-id>, <pub-id pub-id-type="pmid">32358824</pub-id></mixed-citation></ref>
<ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.-M.</given-names></name> <name><surname>Ojha</surname><given-names>S.</given-names></name> <name><surname>Burgess</surname><given-names>C. M.</given-names></name> <name><surname>Sun</surname><given-names>D.-W.</given-names></name> <name><surname>Tiwari</surname><given-names>B. K.</given-names></name></person-group> (<year>2021</year>). <article-title>Inactivation efficacy of plasma-activated water: influence of plasma treatment time, exposure time and bacterial species</article-title>. <source>Int. J. Food Sci. Technol.</source> <volume>56</volume>, <fpage>721</fpage>&#x2013;<lpage>732</lpage>. doi: <pub-id pub-id-type="doi">10.1111/Ijfs.14708</pub-id></mixed-citation></ref>
<ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>R.</given-names></name> <name><surname>Zhou</surname><given-names>R.</given-names></name> <name><surname>Prasad</surname><given-names>K.</given-names></name> <name><surname>Fang</surname><given-names>Z.</given-names></name> <name><surname>Speight</surname><given-names>R.</given-names></name> <name><surname>Bazaka</surname><given-names>K.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Cold atmospheric plasma activated water as a prospective disinfectant: the crucial role of peroxynitrite</article-title>. <source>Green Chem.</source> <volume>20</volume>, <fpage>5276</fpage>&#x2013;<lpage>5284</lpage>. doi: <pub-id pub-id-type="doi">10.1039/C8gc02800a</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0001"><p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1399228/overview">Vladimir Scholtz</ext-link>, University of Chemistry and Technology in Prague, Czechia</p></fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0002"><p>Reviewed by: A. Y. Lavrikova, Swiss Federal Institute of Technology Lausanne, Switzerland</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3275873/overview">Subir Biswas</ext-link>, Ministry of Science and Technology (India), India</p></fn>
</fn-group>
</back>
</article>